Business
DaVita is a kidney-care company built around U.S. dialysis. At December 31, 2025 it served about 200,500 U.S. dialysis patients, operated 2,657 U.S. outpatient dialysis centers, and had international operations in 14 countries.
DaVita grew revenue, but earnings and cash flow fell while buybacks nearly matched FCF.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +6.5% to $13.64BOK
- Profitability — Net income -20.2% to $0.75BWatch
- Cash quality — FCF -10.6% to $1.31BWatch
- Margins — Operating margin -133 bps; net -184 bpsWatch
- Capital — Buybacks -5.6% to $1.31BWatch
- Leverage — Debt +10.8%; equity negativeWatch
- Accounting — Altman grey; no Beneish flagNote
- Insiders — 0 buys / 13 sellsWatch
Leadership changes
From DAVITA INC.'s own filings, the day they're filed.
- DaVita Kidney Care · Chief Operating Officer · appointmenteff. 2024-09-15
- Michael D. Staffieri · Chief Operating Officer · appointmenteff. 2024-09-15
- David P. Maughan · Chief Operating Officer · appointmenteff. 2024-09-15
Latest filings
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-06-08
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about DAVITA INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.